Sepsis treatment: Why change management can lower the lethality of sepsis;Sepsistherapie: Warum change-management die letalität der sepsis senken kann

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 41, Issue 10, 2006, Pages 614-623

  Gerlach, Herwig ^a   Toussaint, Susanne ^b  

^a MARTIN LUTHER KRANKENHAUS   (Germany)

^b VIVANTES KLINIKUM NEUKÖLLN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ACUTE BRAIN DISEASE; EVIDENCE BASED PRACTICE; HUMAN; HYPOXEMIA; INCIDENCE; KIDNEY DYSFUNCTION; METABOLIC ACIDOSIS; MORTALITY; REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SURVIVAL; THROMBOCYTOPENIA;

GERMANY; HUMANS; INCIDENCE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS; SEPSIS; SURVIVAL RATE;

EID: 33750508351     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-955856     Document Type: Review

References (12)

1. Murray CJL, Lopez AD, Mathers CD, Stein C. The Global Burden of Disease 2000 in Aging Populations [online] November 2001. Quelle im Internet: www.hsph.harvard. edu/burdenofdisease/publications/papers/gbd2000.pdf
2. American Cancer Society. Cancer Statistics Slide Set [online] 2002. Quelle inn Internet: www.cancer.org/eprise/main/docroot/PRO/content/ PRO_1_1_Cancer_Statistics_2002_slides.zip?sitearea=PRO25
3. Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD. National Vital Statistics Reports [serial online] 21. September 2007. Quelle im Internet: www.cdc.gov/nchs/data/nvsr/nvsr49/nvsr49_08.pdf
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310
5. Balk RA. Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations. Crit Care Clin 2000;16:179-192
6. Bernard G, Vincent JL, Laterre PF et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 2001;344:699-709
7. Abraham E, Laterre PF, Garg K, Levy H et al. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-1341
8. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-871
9. Rivers E, Nguyen B, Havstad S. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. New Engl J Med 2002;345:1368-1377
10. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. New Engl J Med 2002;345:1359-1367
11. Dellinger RP, Carlet JM, Masur H, Gerlach H et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004;30:536-555
12. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989;95:25-45